Chugai Pharmaceutical Signs Agreement on Combinatorial Chemistry | GenomeWeb

INDIANAPOLIS--Earlier this month, Eli Lilly here announced a deal with Tokyo-based Chugai Pharmaceutical in which the American firm will share proprietary combinatorial chemistry expertise in exchange for up-front fees, milestone payments, and royalties on the first two products that reach the market as a result of the collaboration. Among the techniques and technologies that will be shared are some gained as a result of Lilly's 1994 acquisition of Sphinx Pharmaceuticals, which significantly expanded Lilly's competence in combinatorial chemistry.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.